Lewati ke konten utama

NVRA

NASDAQ

Novara Biotech

Healthcare · Biotechnology

Updated UTC

US$410,77

+5,46+1,35%

After hoursUS$412,82+0,50%

350,00400,0005/2106/2608/0309/0710/1311/18410,77

130 candlesRange +20,09%

Key statistics

Open
US$405,06
High
US$411,55
Low
US$402,66
Previous close
US$405,31
Volume
3,81 jt
Average volume
3,14 jt
Kapitalisasi pasar
393,65 M
P/E ratio
37,55
EPS
US$10,94
Dividend yield
—
52-week high
US$412,94
52-week low
US$295,67

Financial statements

Units: USD · Annual
ItemFY2022FY2023FY2024FY2025FY2026
Revenue31,67 M37,26 M41,96 M48,31 M53,67 M
Gross profit18,76 M21,53 M23,9 M26,46 M32,34 M
Operating income6,26 M7,62 M7,85 M9,58 M11,72 M
Net income4,88 M5,63 M6,17 M5,78 M7,65 M

About the company

Clinical-stage developer of oral therapies for autoimmune and metabolic disorders.

Related news

Demo
  • Novara Biotech reports quarterly revenue above the internal plan

    Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.

    Sector Desk

  • Novara Biotech expands manufacturing capacity in Cambridge

    The company approved a multi-year capital program intended to shorten lead times for its largest customers.

    Sector Desk

  • Analyst note trims Novara Biotech price target on valuation

    A sell-side desk kept a neutral rating while noting that near-term estimates already reflect steady execution.

    Sector Desk

  • Novara Biotech appoints new chief financial officer

    The board named an internal candidate with prior treasury and investor-relations experience to the role.

    Sector Desk

  • Novara Biotech announces share repurchase authorization

    The authorization covers a modest slice of the float and will be funded from operating cash flow.

    Terminal Brief